Name: EnterNext welcomes Poxel on Euronext in Paris
Uploaded: 2015-02-06T09:06:00+0100
Description: Thomas Kuhn, CEO of Poxel, rings the opening bell. Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2014, the group had 6 products including 1 in phase II of clinical development (Imeglimin), 1 in phase of preclinical development (PXL770) and 4 in research phase.

搜索联络表

This page is available in multiple languages

Select Language

Back

06/02/2015

Thomas Kuhn, CEO of Poxel, rings the opening bell.

Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.

At the end of 2014, the group had 6 products including 1 in phase II of clinical development (Imeglimin), 1 in phase of preclinical development (PXL770) and 4 in research phase.